Nektar Therapeutics NKTR
As ofNov 20, 2026, 3:40 PM EST
- YTD
- -28.23%
- 1 year
- -44.94%
5D -3.11 (-8.29%)
- Market cap
- 1.04B
- Revenue (ttm)
- 52.19M
- EPS (ttm)
- -22.47
- Shares out
- 34.21M
- Forward P/E
- -3.28
- YTD return
- -28.23%
- 1-year return
- -44.94%
- 50-day average
- 46.15
- 200-day average
- 65.01
- Enterprise value
- 691.98M
- Volume
- 801.43K
- Avg volume
- 1.11M
- Open
- 31.31
- Previous close
- 32.54
- Day's range
- 30.17 – 31.47
- 52-week range
- 30.17 – 109.00
- Beta
- 1.42
- Analysts
- Buy
- Price target
- 131.92 (+334.7%)
- Earnings date
- Mar 11, 2027
Key statistics
- PEG ratio
- 0.31
- Price / sales
- 21.33
- Price / book
- 1.31
- Revenue growth
- -20.40%
- Free cash flow
- -152.10M
- Total cash
- 614.36M
- Total debt
- 128.67M
- Return on equity
- -37.92%
- Short % of float
- 21.79%
Fundamental scorecard
5 of 25 checks passed on NKTR’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 40.00
- Target (mean)
- 131.92
- Target (high)
- 192.00
- Strong buy1
- Buy10
- Hold4
- Sell0
- Strong sell0
Next earnings
Mar 11, 2027
Expected Mar 11, 2027. Consensus EPS estimate -2.46.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 11, 2027 | Dec 30, 2026 | -2.51 | — | — | — |
| Nov 12, 2026 | Sep 30, 2026 | -2.07 | -1.63 | +0.44 | +21.26% |
| Aug 13, 2026 | Jun 30, 2026 | -1.97 | -1.23 | +0.74 | +37.56% |
| May 7, 2026 | Mar 31, 2026 | -1.58 | -1.82 | -0.24 | -15.02% |
| Mar 12, 2026 | Dec 31, 2025 | -2.47 | -1.78 | +0.69 | +28.05% |
| Nov 6, 2025 | Sep 30, 2025 | -2.85 | -1.85 | +1.00 | +35.09% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 16, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 12, 2026 | UBS | init | — | Neutral |
| Oct 12, 2026 | Leerink Partners | init | — | Outperform |
| Oct 9, 2026 | BTIG | reit | Buy | Buy |
| Oct 9, 2026 | Raymond James | init | — | Market Perform |
| Oct 2, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nektar.com
News
Nektar Therapeutics (NKTR) Presents at UBS Global Biopharma Conference 2026 Transcript Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to $149
NKTR Q3 Earnings Beat Estimates, 2026 Revenue View Cut, Stock Down
Nektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript Nektar Therapeutics Q3 EPS $(1.63) Beats $(2.08) Estimate, Sales $9.386M Miss $10.274M Estimate. Cash and Investments $952.9M
Your note
Sign in to keep a note on NKTR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ROBIN HOWARD W | Chief Executive Officer | Sale | Aug 17, 2026 | 54,655 |
| WILSON MARK ANDREW | Officer | Sale | Nov 24, 2025 | 21,585 |
| ZALEVSKY JONATHAN | Officer | Sale | Aug 17, 2026 | 9,570 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.97% | 5,121,441 | 166.65M | Sep 29, 2026 |
| Two Seas Capital Lp | 9.78% | 3,345,978 | 108.88M | Sep 29, 2026 |
| Blackrock Inc. | 8.39% | 2,871,463 | 93.44M | Sep 29, 2026 |
| BVF Inc. | 6.24% | 2,134,007 | 69.44M | Sep 29, 2026 |
| State Street Corporation | 5.18% | 1,772,302 | 57.67M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.39% | 1,501,608 | 48.86M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 5.41% | 1,850,478 | 60.21M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.14% | 1,075,108 | 34.98M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.85% | 975,224 | 31.73M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.61% | 892,637 | 29.05M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.46% | 500,351 | 16.28M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.24% | 424,554 | 13.81M | Sep 29, 2026 |
